All three pillars are getting squeezed
24/03/20 -"Against the background of the to-be-expected recession, management's lifted dividend proposal of €1.30 per share looks far too optimistic, but, one has to bear in mind, the company is family-owned ..."
Pages
70
Language
English
Published on
24/03/20
You may also be interested by these reports :
17/08/26
The Q2/H1 results surpassed expectations, again driven by the Biosimilars growth engine, as Generics posted muted growth. Also, the management ...
14/08/26
The Q2 results exceeded consensus estimates, driven by a healthy showing from Crop Science, whereas the growth for the other two businesses was ...
14/08/26
Since we last teased this name on 3 January 2025 — arguing there was little incremental upside left after a strong run and a post-merger valuation ...
13/08/26
PolyPeptide released its already-known results, with no surprises. There was strong operational performance, with guidance raised for FY26. The focus ...